Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very well said efood...
You are welcome... I will be here. GLTU
Ken Waggoner joined Nuvilex, now PharmaCyte in November 2013. The questions he was answering were regarding the April 2013 10k. What this confirms for me is that we are very lucky that he took over this company. He has done an amazing job to get us where were are today. I am very thankful to have him as our CEO and know that he has made some major changes since coming on board which are only to our benefit.
TD2 is our CRO and we are not planning to start our clinical trials until the end of the third quarter. We will get more details as we get closer but we are about three months from starting so I don't expect to hear those details for a while.
http://www.td2inc.com/services/clinical
GEN News Highlights
Jun 23, 2015
PharmaCyte Biotech, UTS to Partner on Diabetes Treatment
PharmaCyte Biotech will partner with the University of Technology Sydney (UTS) to co-develop the company’s preclinical treatment for insulin-dependent diabetes that uses its Cell-in-a-Box® technology. The value of the collaboration was not disclosed.
The diabetes treatment consists of Melligen cells—human non-pancreatic insulin-producing cells—developed by UTS researchers, and encapsulated via Cell-in-a-Box, the company’s cellulose-based live cell encapsulation technology.
PharmaCyte Biotech and UTS have signed a research services agreement and a consulting contract. The agreement is designed to fund pivotal studies by Professor Ann Simpson, Ph.D. and colleagues to conduct, with the goal of helping fully characterize the parameters by which Melligen cells produce insulin on-demand when encapsulated using Cell-in-a-Box.
The consulting contract is intended to allow Dr. Simpson to devote sufficient time to working with PharmaCyte Biotech and its international Diabetes Consortium as it pursues development of the company’s diabetes treatment.
“We are particularly pleased that Professor Simpson has agreed to join us as a consultant because, not only was she a founding member of our Diabetes Consortium, her expertise in dealing with the Melligen cells will undoubtedly continue to be indispensable as we move forward in our efforts to find an effective treatment for all those who are in need of insulin to live a normal life,” PharmaCyte Biotech CEO Kenneth L. Waggoner said in a statement.
According to the company, the consortium consists of prominent investigators from institutions in several countries. The consortium was formed to facilitate studies that will be needed before clinical trials can be undertaken on the diabetes treatment.
The company plans to use Cell-in-a-Box as a platform for treatments for diabetes as well as several types of cancer, including advanced, inoperable pancreatic cancer.
PharmaCyte Biotech’s lead product is a pancreatic cancer treatment that involves low doses of the chemotherapy prodrug ifosfamide, together with encapsulated live cells that convert ifosfamide into its active form, in capsules placed as close to the tumor as possible.
The company said it is also developing cancer treatments based on cannabinoids.
http://www.genengnews.com/gen-news-highlights/pharmacyte-biotech-uts-to-partner-on-diabetes-treatment/81251423/
Take a look at this...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98823719
Good news for those doing cannabis medical research...
http://www.huffingtonpost.com/2015/06/22/public-health-service-review_n_7635760.html
The flag for naked short interest in this stock is available for all to see. This is certainly not a normal phenomenon since naked shorting is illegal.
http://www.otcmarkets.com/stock/pmcb/short-sales
zigzag, i believe Marlee is saying exactly what you are saying. Some have have stated that the preclinical results must be negative since nothing has formally been reported but this is illogical.
We would not be moving into human trials and refining preclinical data if the results did not look promising.
Besides, the initial preclinical study reported very good results.
This has been an ongoing conversation. :)
Yes, enough for there to be a rule 4320 flag. That says to me that certain entities may want to see this go lower. Those entities would have the means to do so as well, IMO. I just hate to see folks believing in this stock being true to form when there is potential that entities have interests to continue to drive this lower.
This is why I believe PMCB to be a long term hold. Only when we gain interest of bigger investors will we be able to combat those naked shorts. JMHO
GLTA
In your opinion, if there are naked shorts in a stock, how does that affect the trading? Are charts reliable if that is the case?
This stock just never seems to trade as expected.
Thanks Kaboom. I don't have pm but it's all good...
PharmCyte already has ODD from FDA for Pancreatic Cancer. Evidently, we are on track for FDA approval.
The study to which was referred "analyzed the outcomes of 59 phase III clinical trials of cancer drugs going back 10 years, stratified by the market value of the companies four months prior to trial results being announced."
Cell in a Box(R) is not a cancer drug. It is a delivery device that utilizes an already FDA approved cancer drug. Therefore, the approval for PMCB will be for the treatment combo of ifosfomide (FDA approved) using CIAB (a delivery device). No cancer drug will be seeking approval.
Hopefully, others can follow this logic...
Thanks for your insightful post. I agree. Why so much short selling with little to know profit. Doesn't make sense for it to be your average trader.
That is a very realistic perspective, unfortunately. That is because money is most often the motivator as opposed to the health and well-being of others...
Nice post Bill...
Nice post, should have read yours before I posted mine. :)
Honestly rcstock, I don't know that we will get preclinical trial results. I would not hold my breath. If we move into Phase 1 as planned, that would be my signal that all is well. This is really a long term play here. I am new to biotechs. This is my first and I've been here over a year. Things have progressed much slower than I ever anticipated. Just being honest. What keeps me going is the past data results and all the key players involved as well as ongoing milestone accomplishments like Schedule 1 approval. It is easy for the company to come under attack when folks believe that something should happen but does not. The company has not promised preclinical results and I don't think they are required. So, I just don't want folks to be disappointed if results don't come in July. We may have to wait for human trials before we get results and those are really what will drive this company forward. JMO...
PMCB is not going to be doing human trials with a new cancer drug that needs to be approved. They are using a delivery system, Cell in a Box (R). The drug being used for targeted delivery, ifiosfomide, has been on the market for years. Additonally, targeted delivery has proven to be less toxic than traditional chemotherapy and in past studies we had better results than the current Gold Standard. Also, the Phase 1 trials scheduled with TD2 for later this year are for pain associated with pancreatic cancer and malignant ascites.
I found the article very interesting but must ensure readers see how it does not relate to studies being done here at PMCB.
This video is a good place for all investors to learn the basics about Cell in a Box technology and our work with Dr Von Hoff and TD2.
Nice Pete. Enjoy your time with your family and Happy Father's Day.
I think there is a very good chance of that. We just got a Schedule 1 approval that took a year to approve. The FDA gave us ODD and Moira Gunn did an interview with our officers and has decided to share it through NPR. Connecting the dots, I think there is a very good chance of that. :)
Have a good weekend...
Any explanation would only be speculation as no one really knows. What I do know is the technology is revolutionary, has multiple uses for various cancers and diabetes as well as being supported by world renowned doctors, the FDA and DEA (as evidenced by ODD and Schedule 1 approvals).
Like you, I am holding long. I am in since February 2014. I personally focus on company milestones and players involved and believe we will continue to have volatility until we get some real institutional investors. With NPR getting ready to tell our story nationally, it is evident we are positioning ourselves to become the household name our CEO is envisioning.
This is a very telling statement from the article...
"That’s life in the jungle of Wall Street – the lions eat the gazelles who are too slow."
Bios take time so creating urgency to induce panic is easy.
That is why I love Warren Buffet's philosophy of buying what you believe in and being committed to hold. Otherwise, it is easy to fall for the hype.
“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
Warren Buffett
Very wise words from a long term investor here at PMCB.
"They cannot stop the technology. They can only slow the pps."
And as we know from recent milestones, the technology continues to move forward with success.
The linked blog helps explain tactics used by those in the market to create doubt by affecting the pps.
http://otcshortreport.com/blog/john-lux/a-short-seller-manipulation-technique-used-by-otc-market-makers/
Thinking about the potential here, is it possible there are entities who would want to make it appear that this stock is worthless? One day, they will be powerless to affect the price as big money will jump in. For now, we are little known or highly speculative so it is easy to manipulate the price. Also, look at the daily short report. This stock is shorted daily by a larger percent than most stocks.
So, in the end Uboat, your frame of mind has to be long term to survive holding this one for huge gains. Do whatever you need to do to not let the volatility affect you. After all, this too shall pass. Long term frame of mind should allow you to look past the current day to day contrived trading.
NPR is on the way and we will soon become nationally known. I think many will still wait for human trials and results. Bios take a while. It's going to be one hell of a ride which I believe will end with major gains for all those who bought and held at these ridiculously low prices.
GLTU
http://otcshortreport.com/index.php?index=PMCB&action=view#.VYLkx3BHarU
And the proposed project, directed by Dr Hyslop for which the $1.6 million grant proposal is requested, is entitled...
"Development of a human clinical trial-ready cannabinoid + Cell in a Box(R) cellulose- based live cell encapsulation combination for the targeted treatment of pancreatic, brain and other cancers."
Great DD. This letter requesting grant money for Cannabanoid research is rich with information about the planned studies and players involved.
http://hemplib.org/cdphe-rfa1353/denied/46/CDPHE_MarijuanaGrantProposalHYSLOP_Final.pdf
Great to revisit this recent shareholder update on Cannabanoids since most of us have had Viridis lower on our radar. Today's news brought these studies back to mind...
"Cannabinoids and Cancer
There are numerous examples of useful drugs that have been obtained or developed from plants. For example, the drug quinine, used for many years for the treatment of malaria, was first isolated from the Cinchona tree. The heart disease medication digoxin was derived from the compound digitalis found in the foxglove plant. Useful cancer drugs have also been isolated from plants. These include the vinca alkaloids, vincristine and vinblastine, isolated from the periwinkle plant. Taxol® (paclitaxel), first discovered in the bark of the Pacific yew tree, has come to be used for the treatment of a wide variety of cancers. Importantly, a derivative of paclitaxel known as Abraxane®, in combination with the cancer drug gemcitabine, is now the “gold standard” for the treatment of advanced, inoperable pancreatic cancer. In fact, the gemcitabine plus Abraxane® combination will be compared with Nuvilex’s pancreatic cancer treatment in Nuvilex’s Phase 2b clinical trial of this dreaded disease.
With the well-established history of deriving useful cancer drugs from plant sources, and in an effort to develop a “green” approach to the treatment of cancer, Nuvilex has embarked on a path of research that is designed to capitalize on the medicinal properties of components of Cannabis that are known as cannabinoids. Cannabis and its components have been used in medicine for centuries to treat a wide variety of ailments. Drugs developed from cannabinoids have been approved by drug regulatory authorities to treat medical conditions such as nausea, vomiting and pain for many years. More recently, the scientific literature has become replete with articles that testify to the activity of cannabinoids and cannabinoid-like compounds in the treatment of serious diseases, including cancer.
Nuvilex’s initial plan is to combine the Cell-in-a-Box® encapsulation technology with cannabinoids or cannabinoid-like compounds to develop unique treatments for difficult-to-treat and deadly forms of cancer, such as brain cancer. As with Nuvilex’s use of ifosfamide as the cancer prodrug that must be converted into its cancer-killing form, cannabinoid-based prodrugs will be used with the Cell-in-a-Box® technology in ways that optimize their anticancer properties while minimizing or even eliminating their adverse side effects long associated with chemotherapy.
The research being conducted by Dr. Richard M. Hyslop and other scientists at the University of Northern Colorado under a contract with Nuvilex is progressing well. Through the use of “model” cannabinoids, methods are being developed that will allow the separation and purification of various cannabinoids and cannabinoid-like compounds. In addition, efforts are underway to identify a type of cells that are capable of converting cannabinoid-based prodrugs into their cancer-killing form that will be encapsulated using the Cell-in-a-Box® technology. In the event that a suitable existing type of cell cannot be identified, one will be produced by Austrianova using genetic transformation as was done several years ago to create the cells for Nuvilex’s Phase 2b pancreatic cancer treatment.
Most importantly, Nuvilex recently licensed from Austrianova the exclusive worldwide rights to use the Cell-in-a-Box® technology in combination with cannabinoid and cannabinoid compounds for the development of treatments for diseases and other medical conditions. Nuvilex’s initial efforts to use the Cell-in-a-Box® technology with cannabinoids will be in the area of deadly and difficult-to-treat cancers, such as brain and pancreatic cancer.
Nuvilex has changed the name of its subsidiary Medical Marijuana Sciences, Inc. to Viridis Biotech, Inc. The word “viridis” in Latin means “green.” This name change was made to not only emphasize Nuvilex’s efforts in developing “green” disease treatments, but also to underscore that Nuvilex is not involved in the growth, sales, or distribution of Cannabis or its various products and that Nuvilex is purely a biotech company developing treatments based upon cannabinoids or cannabinoid-like compounds for serious and deadly diseases around the globe.
http://www.pharmacytebiotech.com/shareholder-updates/
Thanks for sharing that info on Dr Gunn. National recognition will help for sure. Would love to get believers with deep pockets involved. The more the word gets out, the more big pharma will have to take note of this little bio and a partnership with one of them would be great.
See the links provided just below your post. Let's all be on the look out for the interview. It is huge if it pans out. No reason to think that it wouldn't since Dr Gunn tweeted the interview herself. ;)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114614001
NPR News, Dr Moira Gunn, interviewed PharmaCyte at the 2015 Bio International convention . Be on the look out for the interview at the biotechnation link below. No air time announced yet so let's be on the alert to share when it does come out. The word is evidently getting around about Cell in a Box (R) technology... Good news for all of us shareholders...
Just recorded an interview with @PharmaCyte about a novel technology for treating advanced pancreatic cancer and diabetes #BIO2015
— Moira Gunn (@biotechnation) June 15, 2015
It's all good. Today's news was very encouraging especially in light of the fact that we can now start doing research with the real thing and doing it in cooperation with the DEA. :)
Just in case this was missed by some, Dr Hyslop is not only conducting research on behalf of our subsidiary, Viridis Biotech, formerly Medical Marijuana Sciences. He is also on the scientific advisory board for Viridis and holds no other position with any other biotech.
"Dr. Richard M. Hyslop, Ph.D. has been Member of Scientific Advisory Board at Medical Marijuana Sciences, Inc since January 2014. Dr. Hyslop is Professor of Chemistry and Biochemistry at the University of Northern Colorado, is the first member of the Scientific Advisory Board of Medical Marijuana Sciences. Dr. Hyslop obtained his Ph.D. degree in biochemistry from the University of Texas. His areas of expertise include anti-cancer drug design, the metabolism of anti-cancer ..."
http://www.bloomberg.com/research/stocks/private/person.asp?personId=253810153&privcapId=345331&previousCapId=228648343&previousTitle=Viridis%20Biotech,%20Inc.
Marijuana Stocks News Oct 29, 2014
PMCB formerly NVLX. I guess we were informed last year that the University had applied for a Schedule 1 in order to conduct research on our behalf with Cell in a Box technology...
Nuvilex, Inc. Engaged in “Cutting Edge” Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
NEW YORK, NY–(Marketwired – October 29, 2014) – Nuvilex, Inc. (NVLX) isn’t letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research. The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex’s Cell-in-a-Box®cellulose-based live cell encapsulation technology.
While waiting for a Schedule 1 license from the DEA in order to conduct research using marijuana, Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at UNC, along with his colleague Dr. Corina Brown are conducting these preclinical studies using model compounds that are similar chemically to the components they are looking for in Cannabis.
Dr. Hyslop said in an interview with the Biz West Newspaper in Northern Colorado, that the idea is to use the model compounds to screen live cells in an effort to find those cells that can eventually be encapsulated. “The type of cell that we’re going to incorporate is going to have a particular type of activity that is capable of converting a component of Cannabis to an active anti-cancer drug. What the research involves is identifying the type of cell that is capable of doing that.”
The goal behind this research is to eventually create a treatment for “solid” tumors using constituents (cannabinoids) of the Cannabis plant and the company’s live-cell encapsulation technology, Cell-in-a-Box. Initially, Nuvilex will target solid tumors of the brain and pancreas.
Dr. Hyslop has been involved in cancer research for more than 35 years and is leading a team of scientists from UNC in what Nuvilex’s CEO calls “cutting edge” research on behalf of the company. Dr. Hyslop, who is a member of the Scientific Advisory Board of Nuvilex’s subsidiary, Medical Marijuana Sciences, is the latest in the biotechnology arena to be impressed by Nuvilex’s Cell-in-a-Box and the role it can play in targeted therapies.
The Cell-in-a-Box technology offers a way to encapsulate live cells capable of converting anticancer prodrugs (those that require metabolic conversion into their cancer-killing forms in order to be effective) in protective, pin-head-sized cocoons.
Nuvilex is using the technology for its treatment for advanced, inoperable pancreatic cancer which combines Cell-in-a-Box and the well-known anticancer prodrug ifosfamide. The company is preparing for late-phase clinical trials using its treatment in early 2015, but it is also using the same treatment in what the company hopes will be groundbreaking preclinical studies to treat the symptoms associated with abdominal cancers, namely slowing the accumulation of malignant ascites fluid common with these cancers, and treating the unbearable pain associated with abdominal cancers.
Drs. Hyslop and Brown will develop cancer treatments that combine the Cell-in-a-Box technology with cannabinoid prodrugs instead of ifosfamide. Their efforts to understand the chemical and biochemical processes involved in the interaction of substances derived from a sustainable plant source, such as Cannabis, with sustainable live cell encapsulation (Cell-in-a-Box) provides the opportunity to develop what Nuvilex is calling a “green” approach to treating cancers like pancreatic, brain, breast, and prostate cancer that affect hundreds of thousands of individuals worldwide each year.
For thousands of years, Cannabis has provided a sustainable source of fiber, food, energy and medicine. The Cannabis plant’s cannabinoid constituents, with the most recognized of these being tetrahdyrocannabinol and cannabidiol, have been documented to possess broad anti-inflammatory, antioxidant, analgesic, nerve-protecting and anticancer properties as well as other therapeutic applications.
Watch Dr. Hyslop’s interview with Biz West discussing Cell-in-a-Box® and preclinical studies at UNC:
Amazing Ken. $PMCB - Groundbreaking on many fronts...
Hi, Bill. Another important milestone achieved under the leadership of Ken Waggoner. I didn't even see this one coming but such a key element needed to move us forward with our cannabis research. I look forward to more news about our research now that we have our Schedule 1 approval. Holding long...
PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License
SILVER SPRING, Md., June 15, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its research partner, the University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) enabling the company to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with Cell-in-a-Box® live cell encapsulation.
Although marijuana (Cannabis) is legal in the state of Colorado, use of Cannabis for research purposes at an institution that has federal grants such as UNC is not permitted by the DEA without a Schedule 1 license. The source for the plant material is regulated by DEA, and this material must be obtained through the National Institute for Drug Abuse. With the DEA license, it is now possible for researchers at UNC to obtain both the plant material and specific cannabinoid reference standards needed to conduct the research.
“As we were applying for the Schedule 1 license, ‘model’ compounds, or cannabinoid look-alikes, were utilized to develop research protocols and screen various biological systems,” noted PharmaCyte Biotech’s Principal Investigator and UNC Professor Richard M. Hyslop, Ph.D. “With the license in-hand, we are beginning experiments using the cannabinoids to reexamine the biological systems for activity as well as explore additional systems suitable for use in combination with the Cell-in-a-Box® platform.”
“We are exceedingly pleased with the work that has been accomplished to date at UNC and congratulate Dr. Hyslop and his colleagues at UNC on successfully obtaining the Schedule 1 license,” said Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer. “Now that we have the ability to isolate potentially useful substances from the Cannabis plant itself, we can continue development of Cannabis-derived prodrugs and engineered human cell lines for use with the versatile Cell-in-a-Box® platform. These types of natural or ‘green’ approaches to fighting disease offer a potentially huge upside for patients who suffer from all kinds of maladies, not the least of which is brain cancer.”
Obtaining a DEA Schedule 1 license is a rigorous process. In addition to outlining a legitimate and worthwhile line of scientific investigation in a formal application, the process at UNC included inspection of the laboratory facilities, review of UNC’s plans for record-keeping and confirmation of facility security. Records accounting for all types and quantities of Cannabis ordered, when and how used and means of disposal must be maintained and available for DEA officials during site visits. The license is renewable annually.
http://finance.yahoo.com/news/pharmacyte-biotech-advances-cannabinoid-research-132500292.html
Great post. All so true for this investment in PMCB...
I have underestimated the time for each milestone at every turn. The point is, there are milestones accomplished regularly which are getting us to our ultimate goal...
I most anticipate the upcoming human trials... But then it will be a long while for those results as well so this quote really speaks to our journey with Cell in a Box technology...
"I have no idea on timing, it's easier to tell what will happen than it is to tell when it will happen." WB
PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.
It was a study that used a colon cancer model to treat malignant ascites, a fluid that is common with abdominal cancers like pancreatic, colon, ovarian and liver cancer that accumulates in the abdominal cavity and causes painful swelling of the stomach. In PharmaCyte Biotech’s corporate video (www.PharmaCyte.com/media), renowned gastroenterologist and oncologist, Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, says that he and a team of doctors and researchers found that they “could virtually cure malignant ascites” in this study.
Readers can find the published preclinical study in Cancer Gene Therapy here: http://www.nature.com/cgt/journal/v13/n1/full/7700849a.html
The preclinical study, commissioned by Bavarian Nordic, used “targeted chemotherapy” to treat malignant ascites just as PharmaCyte biotech does. In the study, words like “complete tumor remission” and “cure” were used to describe the results, so why didn’t Bavarian Nordic continue on with its work?
Well, at the time of the study, Bavarian Nordic, the forerunner to Austrianova, had three in-house technologies: (i) the encapsulation technology; (ii) a retroviral vector technology; and (iii) a poxvirus based delivery platform. As a result of the attacks of 9/11 in the United States, Bavarian Nordic decided to focus strategically on the development of a smallpox vaccine based on its poxvirus platform and chose to divest the other two technologies, which eventually were moved into Austrianova.
Austrianova GmbH, based in Europe then, was focused on one big indication -- namely pancreatic cancer. Executives at Austrianova made the decision then to go straight into a pivotal Phase 3 clinical trial in pancreatic cancer, which would have cost the biotech about $40 million. Austrianova was also working on setting up the GMP manufacturing facility in Frankfurt, Germany, and the firm was working on a veterinary clinical trial in mammary cancer.
Prof. Dr. Walter Gunzburg, the Chairman and Chief Technical Officer at Austrianova, said that the company didn’t have the manpower or the resources to work on malignant ascites in addition to all of its other planned activities. “Despite the exciting results in ascites published by Dr. Matthias Löhr, the financial resources available to the company (Austrianova GmbH) in Europe at that time didn't allow us to pursue this indication. We are very glad that PharmaCyte Biotech has now taken up the baton and is again exploring the use of the Cell-in-a-Box® technology to develop a clinical treatment for malignant ascites.”
If this study sounds familiar, it’s because PharmaCyte is currently in preclinical studies with Translational Drug Development (TD2) in Scottsdale, Arizona, to study how effective its treatment can be on the accumulation of malignant ascites. Dr. Löhr, who is now the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, has been involved with the TD2 study from day one.
In the TD2 study, the company is using an ovarian cancer model and working to develop the parameters needed to enter into clinical trials. Based on comments in press releases from PharmaCyte’s CEO, Kenneth L. Waggoner, the company’s treatment appears promising, and plans are being made to enter the clinic to tackle the challenges that malignant ascites presents to patients who have abdominal tumors.
While the studies performed by Dr. Löhr and his team using the colon cancer model were more than 10 years ago, it is quite stunning to hear that they were not only able to “virtually cure malignant ascites” but they also saw “complete tumor remission in all animals” treated with Cell-in-a-Box® (known as Capcell then) and low doses of ifosfamide on days 2-6.
It’s stunning because more than 10 years ago Cell-in-Box® wasn’t nearly as developed as it is today. The technology is much improved in 2015 with capsules that are completely full with active live cells. So, with a more “potent” Cell in a Box® today, patients suffering from malignant ascites from one of the abdominal tumors that causes the accumulation of this fluid, must be elated to see PharmaCyte Biotech reviving the studies to treat this condition where there is currently no treatment available other than the painful and expensive periodic removal of the fluid in a hospital setting.
http://www.reuters.com/article/2015/06/03/idUSnMKW1c4Sga+1c4+MKW20150603
Interesting.... Thanks for sharing your DD...